Codexis Names William Rothwell VP and General Manager, Biobased Chemicals
REDWOOD CITY, Calif., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that William Rothwell, Ph.D. has joined the company as Vice President and General Manager, Biobased Chemicals, a new position. Dr. Rothwell will be responsible for building and managing a new business by leveraging the Codexis directed evolution platform in the growing field of renewable biobased chemicals. He will report to Alan Shaw, Ph.D., President and Chief Executive Officer.
(Photo: http://photos.prnewswire.com/prnh/20101108/SF96213)
(Photo: http://www.newscom.com/cgi-bin/prnh/20101108/SF96213)
Dr. Rothwell was a member of the Codexis Board of Directors from 2007-2009 as a representative of Royal Dutch Shell plc. He joins Codexis management after a 29-year career with Shell, focused on leadership and strategic development of Shell's global chemical business. He retired from Shell late last year.
Dr. Rothwell most recently served as Vice President of Innovation and Chemicals Technology, Shell Global Solutions, Houston, Texas. In this capacity, he led a 500-person team in five global technology centers in the US, Europe and Asia, and sat on both the Shell Global Solutions and Shell Chemicals Leadership Teams. From 2002-07, he was Vice President/ General Manager of Shell Chemicals Ethylene Oxide/Glycols global business, with responsibility for Shell's $1.5 billion global chemicals business. Previously, he held senior strategic planning and business positions at Shell in London and Houston, including as global General Manager of Strategy, Planning and Ventures for Shell Chemicals. He joined Shell as a chemist in 1980.
Dr. Rothwell holds Bachelor's degrees in mathematics and chemistry from Michigan State University and a Ph.D. in physical chemistry from the Massachusetts Institute of Technology.
"We are delighted to welcome Bill Rothwell back to Codexis, and to his new role on our senior management team," Dr. Shaw said. "As a Board member, he contributed his significant expertise in management and strategic development of technology driven businesses. As we announced October 28, Codexis has acquired the Maxygen directed evolution patent portfolio, which will allow us to fully exploit biobased chemical opportunities. With Bill's leadership and long-term expertise in chemical technology development, Codexis can bring our proven track record to this dynamic and growing market."
Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell. Other potential markets include carbon capture, water treatment and chemicals.
Forward-Looking Statements
This press release contains forward-looking statements relating to our intention to pursue chemical opportunities. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2010, including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contact: Media; Lyn Christenson, [email protected], 650-421-8144 or Saskia Sidenfaden, [email protected], 212-827-3771. Investors; Robert Lawson, [email protected], 650-421-8137
SOURCE Codexis, Inc.
Share this article